Spin-off finds investor

January 10, 2003

Technology commercialisation company BTG will invest in Senexis, a biotechnology company that will develop treatments for ageing-related diseases such as Alzheimer's, Parkinson's and Huntington's.

Senexis, based at the University of Manchester Institute of Science and Technology, has raised £1.4 million from BTG and Catalyst BioMedica Limited to finance its research.

Please login or register to read this article.

Register to continue

Get a month's unlimited access to THE content online. Just register and complete your career summary.

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments

Have your say

Log in or register to post comments